| Biomarker ID | 398 |
| PMID | 19047106 |
| Year | 2008 |
| Biomarker | CX3CL1 |
| Biomarker Basis | Concentration Based (ng/mg) |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.60 (95% CI: 0.47-0.76) |
| Effect on Pathways | Pathways Include:-Binding of chemokines to chemokine receptors,Leptin influence on immune response,TNF-alpha effects on cytokine activity, cell motility, and apoptosis,p53 signaling pathway, Chemokine signaling pathway |
| Experiment | Recurrence Free Survival Vs No Recurrence Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | 183 patients were taken into the study. 82 patients developed reccurance within 5 years and 98 age matched controls (PCA with no recurrance). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | Multivariate Analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CX3CL1 |